Assembly Biosciences (ASMB) Cash & Equivalents (2010 - 2026)

Assembly Biosciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $31.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 32.92% year-over-year to $31.1 million; the TTM figure through Mar 2026 stood at $31.1 million (up 32.92% YoY), while the FY2025 annual figure was $58.4 million, up 52.44% from the prior year.
• Cash & Equivalents was $31.1 million for Q1 2026 at Assembly Biosciences, down from $58.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $58.4 million in Q4 2025 to a low of $18.1 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $33.9 million across 5 years, with a median of $28.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 62.15% in 2023, then jumped 93.26% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $52.4 million in 2022, then tumbled by 62.15% to $19.8 million in 2023, then surged by 93.26% to $38.3 million in 2024, then soared by 52.44% to $58.4 million in 2025, then tumbled by 46.76% to $31.1 million in 2026.
• The last three Cash & Equivalents figures came in at $31.1 million (Q1 2026), $58.4 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.